The Brigham and Women's Hospital, Inc.

The General Hospital Corporation

Boston University

Cognoptix, Inc.

Neuroptix Corporation

Lee E Goldstein

Leo T Chylack, Jr

Ashley I Bush

Stephen D Fantone

Marc David Friedman

Norman C Ford

Evan Sherr

Paul D Hartung

Robert H Webb

Alexander Sergienko

David Simon

Ling Fu

Steven D Fantone

Leo T Chylack

A correlation confocal microscope uses correlated photon pairs to improve resolution. It employs a source of a light beam converging to a point location on a sample, and an objective that gathers light from the point location and generates an image beam. A modulator applies a spatial pattern of modulation to the source light beam to define spatially correlated photons whose spatial correlations are preserved in modulated light gathered from the sample. A filter applies a modulation-selective filter function to the image light beam to generate a filtered light beam of like-modulated photons. A coincidence detector detects temporally coincident photon pairs in the filtered light beam, generating a pulse output that indicates the magnitude of a light-detectable property (such as transmissivity or reflectivity) of the sample at the point location. The modulator may apply phase modulation and the filter may be a phase-sensitive component such as an interferometer.

Correlation confocal microscope

A system for performing quasi-elastic light scattering and fluorescent ligand scanning on a subject's eye includes a light source configured to transmit light toward the subject's eye, a lens configured to focus light sent from the source and scattered by the subject's eye, a measurement reflector disposed to receive at least a portion of the focused light and configured to reflect a first portion of the received light, a camera configured and disposed to receive the first portion of the received light and configured to provide indicia of an image corresponding to the first portion of the received light, and a processor coupled to the camera and configured to analyze intensities of light in the image to determine a location of a reference point corresponding to an interface of a portion of the eye.

Ocular imaging

The invention provides methods for diagnosing tumors in mammals using a reagent that bind to LEDGF/p75 or to a nucleic acid encoding LEDGF/p75. For example, the tumor may be located in the CNS, the prostate, the skin, the bone marrow, or the gut of the mammal. Also provided are methods for diagnosing brain tumors such as medulloblastomas, meningiomas, astrocytomas, glioblastomas multiforme, and ependymomas by examining LEDGF/p75 or a nucleic acid encoding LEDGF/p75 localization. The invention also involves methods for diagnosing cancers involving cancerous epithelial cells such as colon cancer. The instant invention also provides methods for isolating stem cells from a heterogeneous population of cells, as well as methods for identifying neuroepithelial stem cells, newly differentiated neurons, and astrocytes in a subject. Also provided are methods for inducing the differentiation of neuroepithelial stem cells into astrocytes or neurons and methods for screening candidate compounds that regulate the differentiation of neuroepithelial stem cells.

Compositions and methods for diagnosing tumors using LEDGF/p75

The invention provides a method of diagnosing, prognosing, staging, and/or monitoring a mammalian amyloidogenic disorder or a predisposition thereto by detecting a protein or polypeptide aggregate in the cortical and/or supranuclear regions of an ocular lens of the mammal.

Methods for diagnosing a neurodegenerative condition

The invention features a method of diagnosing or providing a prognosis regarding the state of Alzheimer's Disease in a mammal by contacting an ocular tissue with a detectably-labeled compound, which binds to an amyloid protein. An increase in binding of the compound to the ocular tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease.

Ocular diagnosis of Alzheimer's disease

Described are methods for the identification of agents useful in the treatment or prevention of cataracts. Also described are methods for the identification of agents that may inadvertently promote or accelerate the formation of cataracts, and methods of treating or preventing injuries to or diseases of the ocular lens, retina and/or macula. More specifically, the invention describes methods for the identification of pharmacological agents useful in treating cataracts by inhibiting the cross-linking of eye lens proteins.

Method for the identification of agents that inhibit or promote cataracts and uses thereof

A method of diagnosing, prognosing, staging, and/or monitoring a mammalian amyloidogenic disorder or a predisposition thereto by detecting a protein or polypeptide aggregate in the cortical and/or supranuclear regions of an ocular lens of the mammal.

Growing community of inventors

Marblehead, MA, United States of America

Lee E Goldstein